More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

Compugen Ltd (NASDAQ:CGEN) reported encouraging data from their studies on COM701, COM902, and pembrolizumab in patients with ...

The per-protocol interim analysis in the pivotal Phase 3 trial (IOB-013/KN-D18), which is evaluating IO102-IO103 in combination with KEYTRUDA ® (pembrolizumab) in advanced melanoma, was completed by ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), retaining the price target of ...